A new study has shown that patients with heart failure overestimate their own life expectancy by around 40% compared with HF-model–based predictions for survival. Heartwire
In over 400 randomized trials, less than one-fifth included CV events, death, pain, function, or another quality-of-life end point as the primary-outcome measure. Researchers say a consensus initiative is warranted to mandate hard clinical end points in major trials. Heartwire
The inotropic and lusitropic istaroxime safely improved hemodynamics as well as systolic and, perhaps, diastolic function in the HORIZON-HF trial, now formally published. Heartwire
New research suggests that a Mediterranean-style diet may protect against new-onset diabetes and that benefits of the diet may be particularly pronounced in people with more risk factors for diabetes. Medscape Medical News
The occurrence of vasomotor menopausal complaints is associated with a less favorable cardiovascular risk profile, researchers report in the June issue of Hypertension. Reuters Health Information
The new oral anticoagulant showed superior efficacy compared with the US-approved dosing regimen of enoxaparin in preventing VTE in patients who had undergone total-knee-replacement surgery. Heartwire
Mean HbA1c of 6.5% was associated with a decreased risk for microvascular complications, but risks for myocardial infarction and stroke were unaffected. Medscape Medical News
Medscape interviews Dr. Kalantar-Zadeh on the effects of vitamin D receptor activators (VDRAs) on bone and mineral metabolism and survival in ESRD patients with secondary hyperparathyroidism. Medscape Nephrology
